LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Regulus Therapeutics Inc

Open

7.86 0.26

Overview

Share price change

24h

Current

Min

7.84

Max

7.87

Key metrics

By Trading Economics

Income

-13M

Sales

340K

340K

EPS

-0.15

Profit margin

-3,762.059

Employees

34

EBITDA

-13M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+12.1% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

310M

545M

Previous open

7.6

Previous close

7.86

Regulus Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

30 Apr 2025, 16:35 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 Apr 2025, 11:55 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 Apr 2025, 11:54 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire Regulus in $1.7 Billion Deal

30 Apr 2025, 11:40 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 Apr 2025, 11:39 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire Regulus in $1.7B Deal

30 Apr 2025, 11:16 UTC

Acquisitions, Mergers, Takeovers

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 Apr 2025, 11:15 UTC

Acquisitions, Mergers, Takeovers

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 Apr 2025, 11:14 UTC

Acquisitions, Mergers, Takeovers

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 Apr 2025, 11:13 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Regulus Therapeutics

Peer Comparison

Price change

Regulus Therapeutics Inc Forecast

Price Target

By TipRanks

12.1% upside

12 Months Forecast

Average 8.8 USD  12.1%

High 11 USD

Low 7 USD

Based on 6 Wall Street analysts offering 12 month price targets forRegulus Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

1

Buy

5

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.